Market Closed -
Nasdaq
04:00:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
3.36
USD
|
+1.20%
|
|
+2.13%
|
+34.40%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
224.2
|
383.6
|
664.8
|
494
|
555.3
|
865.1
|
-
|
-
|
Enterprise Value (EV)
1 |
224.2
|
383.6
|
664.8
|
494
|
555.3
|
865.1
|
865.1
|
865.1
|
P/E ratio
|
-0.93
x
|
-3.58
x
|
-4.68
x
|
-5.04
x
|
-5.54
x
|
-8.58
x
|
-8.54
x
|
-7.78
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
27.8
x
|
44
x
|
47.8
x
|
9.3
x
|
22.5
x
|
95.7
x
|
107
x
|
73.5
x
|
EV / Revenue
|
27.8
x
|
44
x
|
47.8
x
|
9.3
x
|
22.5
x
|
95.7
x
|
107
x
|
73.5
x
|
EV / EBITDA
|
-2,407,062
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-2,336,661
x
|
-5,893,587
x
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
2.67
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
62,112
|
84,909
|
135,269
|
156,467
|
167,695
|
188,717
|
-
|
-
|
Reference price
2 |
3.610
|
4.518
|
4.915
|
3.157
|
3.312
|
4.584
|
4.584
|
4.584
|
Announcement Date
|
3/5/20
|
3/4/21
|
3/3/22
|
3/2/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
8.061
|
8.718
|
13.92
|
53.12
|
24.63
|
9.038
|
8.082
|
11.77
|
EBITDA
|
-93.16
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-193.2
|
-72.89
|
-93.12
|
-89.11
|
-106
|
-107.2
|
-110.9
|
-125.5
|
Operating Margin
|
-2,396.84%
|
-836.07%
|
-669.11%
|
-167.75%
|
-430.53%
|
-1,185.84%
|
-1,372.32%
|
-1,066.36%
|
Earnings before Tax (EBT)
1 |
-223.1
|
-80.38
|
-96.57
|
-88.51
|
-98.9
|
-98.94
|
-102.5
|
-116.2
|
Net income
1 |
-221.1
|
-95.66
|
-111.9
|
-94.56
|
-98.9
|
-98.69
|
-101.6
|
-116.1
|
Net margin
|
-2,742.84%
|
-1,097.31%
|
-804.39%
|
-178.01%
|
-401.57%
|
-1,091.98%
|
-1,257.71%
|
-985.92%
|
EPS
2 |
-3.875
|
-1.261
|
-1.051
|
-0.6263
|
-0.5974
|
-0.5342
|
-0.5370
|
-0.5890
|
Free Cash Flow
|
-95.97
|
-65.09
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-1,190.59%
|
-746.64%
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/5/20
|
3/4/21
|
3/3/22
|
3/2/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
4.06
|
16.15
|
18.31
|
8.009
|
8.502
|
9.107
|
6.202
|
6.37
|
2.912
|
2.108
|
2.411
|
2.313
|
2.189
|
2.342
|
2.342
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-26.34
|
-14.09
|
-18.14
|
-23.97
|
-30.72
|
-23.72
|
-24.51
|
-29.48
|
-28.17
|
-26.64
|
-26.74
|
-26.98
|
-26.95
|
-26.47
|
-26.43
|
Operating Margin
|
-648.66%
|
-87.23%
|
-99.07%
|
-299.24%
|
-361.28%
|
-260.4%
|
-395.29%
|
-462.82%
|
-967.23%
|
-1,263.9%
|
-1,108.94%
|
-1,166.3%
|
-1,231.27%
|
-1,130.29%
|
-1,128.68%
|
Earnings before Tax (EBT)
1 |
-27
|
-14.53
|
-18.24
|
-23.64
|
-29.86
|
-22.25
|
-22.79
|
-27.49
|
-26.22
|
-24.6
|
-24.68
|
-24.92
|
-24.88
|
-24.43
|
-24.39
|
Net income
1 |
-27.73
|
-20.24
|
-18.24
|
-23.64
|
-29.86
|
-22.25
|
-22.79
|
-27.49
|
-26.22
|
-24.6
|
-24.65
|
-24.89
|
-24.86
|
-24.41
|
-24.37
|
Net margin
|
-682.94%
|
-125.31%
|
-99.66%
|
-295.14%
|
-351.19%
|
-244.34%
|
-367.53%
|
-431.6%
|
-900.33%
|
-1,166.77%
|
-1,022.59%
|
-1,076.02%
|
-1,135.56%
|
-1,042.15%
|
-1,040.55%
|
EPS
2 |
-0.1900
|
-0.1412
|
-0.1286
|
-0.1615
|
-0.1906
|
-0.1362
|
-0.1333
|
-0.1641
|
-0.1629
|
-0.1376
|
-0.1314
|
-0.1314
|
-0.1314
|
-0.1323
|
-0.1277
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/3/22
|
5/5/22
|
8/4/22
|
11/9/22
|
3/2/23
|
5/4/23
|
8/3/23
|
11/7/23
|
2/29/24
|
5/2/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-96
|
-65.1
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
1.690
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.79
|
0.29
|
1.03
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
9.79%
|
3.31%
|
7.37%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/5/20
|
3/4/21
|
3/3/22
|
3/2/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
4.584
CAD Average target price
6.029
CAD Spread / Average Target +31.53% Consensus |
1st Jan change
|
Capi.
|
---|
| +34.40% | 634M | | -2.29% | 89.87B | | -3.95% | 37.57B | | -13.07% | 32.75B | | +63.05% | 26.47B | | -22.14% | 14.25B | | -7.96% | 12.99B | | -9.33% | 11.93B | | -46.33% | 10.84B | | +5.77% | 9.11B |
Biopharmaceuticals
|